ArticleJournal of bone and mineral metabolism2015
Atypical femoral fracture in a patient treated with denosumab.
Article in Journal of bone and mineral metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.The Journal of clinical endocrinology and metabolism · 2020Guideline
- Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review.BMC cancer · 2019Pooled it
- Trial
- Bilateral Atypical Femoral Fracture in a Bisphosphonate-Naïve Patient with Prior Long-Term Denosumab Therapy: A Case Report of the Management Strategy and a Literature Review.Journal of clinical medicine · 2024Article
- Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents.Journal of bone oncology · 2023Article
- Bilateral Atypical Femur Fractures After Denosumab in a Bisphosphonate Naive Patient: A Case Report.Calcified tissue international · 2022Article
- Gene Network of Susceptibility to Atypical Femoral Fractures Related to Bisphosphonate Treatment.Genes · 2022Article
- Should denosumab treatment for osteoporosis be continued indefinitely?Therapeutic advances in endocrinology and metabolism · 2021Review
- Multiple ipsilateral femoral stress fractures in a patient taking denosumab for osteoporosis-a case report.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020Article
- Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report.Journal of bone oncology · 2020Article
- Clinical Features and Outcomes of Bilateral Atypical Femoral Fractures.Case reports in orthopedics · 2020Article
- New and emerging concepts in the use of denosumab for the treatment of osteoporosis.Therapeutic advances in musculoskeletal disease · 2018Review
- Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.Current osteoporosis reports · 2018Review
- Management of atypical femoral fracture in a patient with osteogenesis imperfecta.BMJ case reports · 2017Article
- Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis.Breast cancer (Tokyo, Japan) · 2017Article
- Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab.Acta orthopaedica · 2017Article
- Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy.The oncologist · 2017Article
- Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017Article
- Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016Article
- Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor.Asian spine journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical fractures of the femur (AFF) have been reported in the literature at an increasing rate over the past decade, especially in patients who have been on prolonged courses of bisphosphonates. However, there have only been a few reported cases of AFF in those treated with other antiresorptive medications. In this case report, a 72-year-old woman with chronic obstructive pulmonary disease and osteoporosis presented with an atraumatic right femoral fracture in the setting of denosumab use. In contrast with other reports, this patient had received bisphosphonate therapy for a short duration before the switch to denosumab. While causality between the fracture and denosumab use cannot be established in this case, there is a growing number of reports of a similar association. Ongoing vigilance is required to determine whether denosumab is associated with or potentially a cause of AFF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.